Pfizer’s (PFE) “Outperform” Rating Reaffirmed at BMO Capital Markets

BMO Capital Markets reiterated their outperform rating on shares of Pfizer (NYSE:PFE) in a research note published on Thursday morning, Benzinga reports. The firm currently has a $36.00 target price on the biopharmaceutical company’s stock, up from their previous target price of $33.00.

Other equities research analysts have also issued reports about the company. Argus lowered Pfizer from a buy rating to a hold rating in a report on Friday, March 22nd. TD Cowen cut shares of Pfizer from an outperform rating to a market perform rating and set a $32.00 price objective for the company. in a research note on Thursday, January 4th. Cantor Fitzgerald reiterated an overweight rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a buy rating and a $36.00 target price for the company. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $36.00.

Pfizer Stock Up 0.4 %

Shares of NYSE PFE traded up $0.11 during trading hours on Thursday, hitting $27.81. The stock had a trading volume of 60,568,852 shares, compared to its average volume of 41,900,304. The company has a market capitalization of $157.48 billion, a P/E ratio of -463.42, a P/E/G ratio of 1.18 and a beta of 0.63. The firm’s 50-day moving average price is $26.88 and its two-hundred day moving average price is $28.21. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer has a 52 week low of $25.20 and a 52 week high of $40.37.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The business had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the firm earned $1.23 EPS. Pfizer’s revenue for the quarter was down 19.5% on a year-over-year basis. Analysts anticipate that Pfizer will post 2.36 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 annualized dividend and a dividend yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

Institutional Investors Weigh In On Pfizer

Several large investors have recently modified their holdings of the stock. Trifecta Capital Advisors LLC grew its holdings in shares of Pfizer by 3.7% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 325 shares during the last quarter. Confluence Wealth Services Inc. increased its holdings in shares of Pfizer by 0.5% during the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company’s stock worth $2,158,000 after buying an additional 342 shares in the last quarter. Carr Financial Group Corp raised its stake in shares of Pfizer by 3.3% in the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company’s stock valued at $344,000 after acquiring an additional 355 shares during the last quarter. Caldwell Sutter Capital Inc. boosted its holdings in shares of Pfizer by 0.5% in the 3rd quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company’s stock worth $2,315,000 after acquiring an additional 364 shares in the last quarter. Finally, Advisor OS LLC grew its position in Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after acquiring an additional 365 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.